Decision Resources, Inc., one of the world's leading research and advisory firms focusing on pharmaceutical and health care issues, forecasts that launches of novel bone-forming agents, such as Eli Lilly's Forteo (teriparatide) will play a major role in driving the growth of the osteoporosis market. More specifically, Forteo will command premium pricing and sales of the drug could reach $2 billion in 2011.

(Photo: http://www.newscom.com/cgi-bin/prnh/20000303/DECISION )

"Although Lilly's Forteo will only be prescribed to patients with severe osteoporosis, and in a self-injectable form that may discourage patient compliance, the drug still has the potential to reach sales of $2 billion in 2011," said Carilee Berg, Ph.D., analyst at Decision Resources. "The commercial success of this drug will be driven by its premium pricing. Specialists are eagerly awaiting the launch of Forteo, which will be the first bone-forming agent to reach the market."

The new Pharmacor study, entitled Osteoporosis, also found that the prevalent osteoporosis population will grow from 46 million in 2001 to approximately 57 million in 2011 as the general population ages and as increases in life expectancy expand the pool of elderly people -- the subpopulation most susceptible to the disease.

Disease Background-Osteoporosis

Each year, osteoporosis leads to more than 1.5 million fractures in the United States alone, resulting in direct medical costs of $17 billion -- a figure comparable to the direct costs of other chronic conditions (e.g. asthma, congestive heart failure). Although the risks and costs associated with osteoporosis are significant, less than 50% of the prevalent population is diagnosed. This low diagnosis rate results in part from the perception that osteoporosis is a normal consequence of aging and therefore is not a preventable or treatable disease.

About Pharmacor from Decision Resources

Pharmacor is a unique family of studies based on primary and secondary research conducted by Decision Resources' on-staff experts. Each comprehensive study assesses a host of market-impacting factors and analyzes the commercial outlook for drugs in research and development. Cardium, Cognos, Immune and Inflammatory Disorders, Infectious Disease, Metabolic Disorders, Psychiatric Disorders, and Onkos concentrate on specific therapeutic areas. Mosaic covers high-interest disease states. Osteoporosis is a Metabolic Disorders study.

About Decision Resources

Decision Resources, Inc., is a world leader in research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. The company provides strategic information services, and assesses international pharmaceutical and health care industry trends. Visit Decision Resources at www.decisionresources.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

  For more information, contact:    Elizabeth Marshall    Decision Resources, Inc.    781-296-2563    emarshall@dresources.com 

Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/20000303/DECISION
AP Archive: http://photoarchive.ap.org/
PRN Photo Desk, 888-776-6555 or 212-782-2840

SOURCE: Decision Resources, Inc.

CONTACT: Elizabeth Marshall of Decision Resources, Inc., +1-781-296-
2563, emarshall@dresources.com

New PPO Product Captures A Comprehensive Managed Care Picture

View Now